NASDAQ:ARCT Arcturus Therapeutics (ARCT) Stock Forecast, Price & News $26.88 -0.19 (-0.70%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$26.45▼$27.6650-Day Range$15.50▼$32.3652-Week Range$11.70▼$33.80Volume307,594 shsAverage Volume418,086 shsMarket Capitalization$713.93 millionP/E Ratio6.64Dividend YieldN/APrice Target$32.25 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainShort InterestSocial Media Arcturus Therapeutics MarketRank™ ForecastAnalyst RatingHold2.30 Rating ScoreUpside/Downside20.0% Upside$32.25 Price TargetShort InterestBearish13.76% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.46Based on 5 Articles This WeekInsider TradingSelling Shares$1.05 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.62) to ($6.25) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.81 out of 5 starsMedical Sector712th out of 983 stocksPharmaceutical Preparations Industry354th out of 486 stocks 2.2 Analyst's Opinion Consensus RatingArcturus Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.30, and is based on 6 buy ratings, 1 hold rating, and 3 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $32.25, Arcturus Therapeutics has a forecasted upside of 20.0% from its current price of $26.88.Amount of Analyst CoverageArcturus Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted13.76% of the float of Arcturus Therapeutics has been sold short.Short Interest Ratio / Days to CoverArcturus Therapeutics has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in Arcturus Therapeutics has recently increased by 5.73%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldArcturus Therapeutics does not currently pay a dividend.Dividend GrowthArcturus Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ARCT. Previous Next 3.0 News and Social Media Coverage News SentimentArcturus Therapeutics has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Arcturus Therapeutics this week, compared to 3 articles on an average week.Search Interest18 people have searched for ARCT on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows5 people have added Arcturus Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arcturus Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,045,508.00 in company stock.Percentage Held by Insiders12.20% of the stock of Arcturus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions83.74% of the stock of Arcturus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Arcturus Therapeutics are expected to decrease in the coming year, from ($2.62) to ($6.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcturus Therapeutics is 6.64, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 130.45.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcturus Therapeutics is 6.64, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 105.35.Price to Book Value per Share RatioArcturus Therapeutics has a P/B Ratio of 2.17. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Arcturus Therapeutics (NASDAQ:ARCT) StockArcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.Read More Receive ARCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcturus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ARCT Stock News HeadlinesJune 2, 2023 | msn.comHC Wainwright & Co. Reiterates Arcturus Therapeutics Holdings (ARCT) Buy RecommendationJune 2, 2023 | americanbankingnews.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $30.57 Average Price Target from AnalystsJune 4, 2023 | Legacy Research (Affiliate) (Ad)“Amazon Loophole” could hand you $28,544 in “royalty” payoutsThanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.June 1, 2023 | msn.comArcturus Therapeutics receives FDA fast track status for ARCT-810June 1, 2023 | finance.yahoo.comArcturus Therapeutics Receives U.S. FDA Fast Track Designation for ARCT-810, mRNA Therapeutic Candidate for Ornithine Transcarbamylase DeficiencyMay 26, 2023 | fool.comArcturus Therapeutics (NASDAQ: ARCT)May 19, 2023 | markets.businessinsider.comChinook Therapeutics (KDNY) Gets a Buy from Piper SandlerMay 19, 2023 | markets.businessinsider.comProtagonist Therapeutics (PTGX) Gets a Buy from Piper SandlerJune 4, 2023 | Stocks To Trade (Ad)15 A.I. Trading Opportunities a DayUsing our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.May 19, 2023 | americanbankingnews.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Expected to Earn FY2023 Earnings of ($2.58) Per ShareMay 18, 2023 | finance.yahoo.comGrowth Investors: Industry Analysts Just Upgraded Their Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Revenue Forecasts By 76%May 17, 2023 | americanbankingnews.comArcturus Therapeutics (NASDAQ:ARCT) Rating Reiterated by Cantor FitzgeraldMay 17, 2023 | americanbankingnews.comCantor Fitzgerald Reiterates Overweight Rating for Arcturus Therapeutics (NASDAQ:ARCT)May 17, 2023 | americanbankingnews.comResearch Analysts Set Expectations for Arcturus Therapeutics Holdings Inc.'s Q2 2023 Earnings (NASDAQ:ARCT)May 16, 2023 | americanbankingnews.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Short Interest Up 11.7% in AprilMay 12, 2023 | msn.comHC Wainwright & Co. Upgrades Arcturus Therapeutics Holdings (ARCT)May 12, 2023 | finance.yahoo.com4 big analyst picks: Albemarle scores fresh Overweight ratingMay 12, 2023 | americanbankingnews.comStockNews.com Downgrades Arcturus Therapeutics (NASDAQ:ARCT) to HoldMay 11, 2023 | markets.businessinsider.comRobert W. Baird Reaffirms Their Sell Rating on Arcturus Therapeutics (ARCT)May 11, 2023 | markets.businessinsider.comAnalyst's Vote of Confidence: Arcturus' COVID-19 Vaccine Efforts Set to Pay Off in Japan and BeyondMay 11, 2023 | americanbankingnews.comArcturus Therapeutics (NASDAQ:ARCT) Raised to Buy at HC WainwrightMay 10, 2023 | finance.yahoo.comArcturus Therapeutics (ARCT) Q1 Earnings and Revenues Miss EstimatesMay 9, 2023 | benzinga.comArcturus Therapeutics: Q1 Earnings InsightsMay 9, 2023 | finance.yahoo.comArcturus Therapeutics Announces First Quarter 2023 Financial Update and Pipeline ProgressMay 8, 2023 | finance.yahoo.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?May 8, 2023 | americanbankingnews.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $28.25 Consensus Price Target from AnalystsMay 6, 2023 | americanbankingnews.comInsider Selling: Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) COO Sells $129,650.00 in StockSee More Headlines ARCT Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARCT Company Calendar Last Earnings3/28/2023Today6/04/2023Next Earnings (Estimated)8/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ARCT CUSIPN/A CIK1410997 Webwww.arcturusrx.com Phone(858) 900-2660FaxN/AEmployees177Year FoundedN/APrice Target and Rating Average Stock Price Forecast$32.25 High Stock Price Forecast$51.00 Low Stock Price Forecast$14.00 Forecasted Upside/Downside+20.0%Consensus RatingHold Rating Score (0-4)2.30 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)$4.05 Trailing P/E Ratio6.64 Forward P/E RatioN/A P/E GrowthN/ANet Income$9.35 million Net Margins39.59% Pretax Margin40.09% Return on Equity36.88% Return on Assets21.77% Debt Debt-to-Equity RatioN/A Current Ratio4.71 Quick Ratio4.71 Sales & Book Value Annual Sales$206 million Price / Sales3.47 Cash Flow$0.41 per share Price / Cash Flow66.10 Book Value$12.40 per share Price / Book2.17Miscellaneous Outstanding Shares26,560,000Free Float23,322,000Market Cap$713.93 million OptionableOptionable Beta2.60 Key ExecutivesJoseph E. PaynePresident, Chief Executive Officer & DirectorPadmanabh ChivukulaSecretary, Chief Operating & Scientific OfficerAndrew H. SassineChief Financial Officer & DirectorDushyant B. VarshneyChief Technology Office & Executive VPKevin T. SkolChief Business OfficerKey CompetitorsArdelyxNASDAQ:ARDXLyell ImmunopharmaNASDAQ:LYELRAPT TherapeuticsNASDAQ:RAPTAmneal PharmaceuticalsNYSE:AMRXDyne TherapeuticsNASDAQ:DYNView All CompetitorsInsiders & InstitutionsPrelude Capital Management LLCBought 12,594 shares on 6/1/2023Ownership: 0.047%Ameriprise Financial Inc.Sold 6,722 shares on 5/22/2023Ownership: 0.033%JPMorgan Chase & Co.Sold 1,337 shares on 5/18/2023Ownership: 1.287%Geode Capital Management LLCBought 18,177 shares on 5/16/2023Ownership: 1.762%Snowden Capital Advisors LLCSold 6,489 shares on 5/16/2023Ownership: 0.035%View All Insider TransactionsView All Institutional Transactions ARCT Stock - Frequently Asked Questions Should I buy or sell Arcturus Therapeutics stock right now? 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last year. There are currently 3 sell ratings, 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ARCT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ARCT, but not buy additional shares or sell existing shares. View ARCT analyst ratings or view top-rated stocks. What is Arcturus Therapeutics' stock price forecast for 2023? 10 brokers have issued twelve-month target prices for Arcturus Therapeutics' shares. Their ARCT share price forecasts range from $14.00 to $51.00. On average, they predict the company's share price to reach $32.25 in the next year. This suggests a possible upside of 20.0% from the stock's current price. View analysts price targets for ARCT or view top-rated stocks among Wall Street analysts. How have ARCT shares performed in 2023? Arcturus Therapeutics' stock was trading at $16.96 at the beginning of 2023. Since then, ARCT shares have increased by 58.5% and is now trading at $26.88. View the best growth stocks for 2023 here. Are investors shorting Arcturus Therapeutics? Arcturus Therapeutics saw a increase in short interest in May. As of May 15th, there was short interest totaling 3,320,000 shares, an increase of 5.7% from the April 30th total of 3,140,000 shares. Based on an average daily volume of 521,600 shares, the short-interest ratio is presently 6.4 days. Currently, 13.8% of the shares of the stock are sold short. View Arcturus Therapeutics' Short Interest. When is Arcturus Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023. View our ARCT earnings forecast. How were Arcturus Therapeutics' earnings last quarter? Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) issued its quarterly earnings data on Tuesday, March, 28th. The biotechnology company reported $4.33 EPS for the quarter, beating the consensus estimate of ($1.86) by $6.19. The biotechnology company had revenue of $160.29 million for the quarter, compared to the consensus estimate of $134.54 million. Arcturus Therapeutics had a net margin of 39.59% and a trailing twelve-month return on equity of 36.88%. What ETFs hold Arcturus Therapeutics' stock? ETFs with the largest weight of Arcturus Therapeutics (NASDAQ:ARCT) stock in their portfolio include Direxion mRNA ETF (MSGR), Direxion Moonshot Innovators ETF (MOON), ARK Genomic Revolution ETF (ARKG), Virtus LifeSci Biotech Clinical Trials ETF (BBC), AXS Green Alpha ETF (NXTE), ETFMG Treatments Testing and Advancements ETF (GERM), WisdomTree BioRevolution Fund (WDNA) and SPDR S&P Biotech ETF (XBI). What is Joe Payne's approval rating as Arcturus Therapeutics' CEO? 11 employees have rated Arcturus Therapeutics Chief Executive Officer Joe Payne on Glassdoor.com. Joe Payne has an approval rating of 90% among the company's employees. 70.0% of employees surveyed would recommend working at Arcturus Therapeutics to a friend. What other stocks do shareholders of Arcturus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), Pfizer (PFE), OPKO Health (OPK), NVIDIA (NVDA), Abbott Laboratories (ABT), CRISPR Therapeutics (CRSP) and What is Arcturus Therapeutics' stock symbol? Arcturus Therapeutics trades on the NASDAQ under the ticker symbol "ARCT." Who are Arcturus Therapeutics' major shareholders? Arcturus Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Federated Hermes Inc. (17.99%), State Street Corp (8.43%), ARK Investment Management LLC (7.48%), BlackRock Inc. (6.76%), Sumitomo Mitsui Trust Holdings Inc. (5.35%) and Nikko Asset Management Americas Inc. (5.35%). Insiders that own company stock include Andy Sassine, Joseph E Payne, Keith C Kummerfeld, Magda Marquet, Pad Chivukula and Ultragenyx Pharmaceutical Inc. View institutional ownership trends. How do I buy shares of Arcturus Therapeutics? Shares of ARCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Arcturus Therapeutics' stock price today? One share of ARCT stock can currently be purchased for approximately $26.88. How much money does Arcturus Therapeutics make? Arcturus Therapeutics (NASDAQ:ARCT) has a market capitalization of $713.93 million and generates $206 million in revenue each year. The biotechnology company earns $9.35 million in net income (profit) each year or $4.05 on an earnings per share basis. How many employees does Arcturus Therapeutics have? The company employs 177 workers across the globe. How can I contact Arcturus Therapeutics? Arcturus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.arcturusrx.com. The biotechnology company can be reached via phone at (858) 900-2660 or via email at ir@arcturusrx.com. This page (NASDAQ:ARCT) was last updated on 6/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcturus Therapeutics Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.